3 Notable Runners: Sage Therapeutics, Inc. (SAGE), Cynosure, Inc. (CYNO), People’s United Financial, Inc. (PBCT)

Sage Therapeutics, Inc. (SAGE) managed to rebound with the stock climbing 11.75% or $5.57 to close the day at $52.99 on lower than average trading volume of 2.44M shares, compared to its three month average trading volume of 491.74K. The  based company has been outperforming the biotechnology companies by 3.1422% for last three months and its recent gains have pushed the stock slightly up 3.78% YTD, versus the biotechnology industry which is down -2.82% for the same period. The RSI of 63.07 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedation are desirable prior to the introduction of general anesthesia. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Cynosure, Inc. (CYNO) had a light trading with around 2.43M shares changing hands compared to its three month average trading volume of 648.92K. The stock traded between $49.25 and $52.9 before closing at the price of $51.5 with -6.45% change on the day. The Westford Massachusetts 01886 based company is currently trading 49.41% above its 52 week low of $34.47 and -7.94% below its 52 week high of $55.94. Both the RSI indicator and target price of 55.59 and $59.13 respectively, lead us to believe that it should be put on hold over the coming weeks.

Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. The company’s aesthetic treatment systems utilize a range of energy sources, including Alexandrite, diode, Nd: YAG, pulse dye, Q-switched lasers, intense pulsed light, and radiofrequency (RF) technology. It offers Elite product line for hair removal, and treatment of facial and leg veins and pigmentations; SmartLipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; Cynergy product line for the treatment of vascular lesions; MedLite C6 and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos; and PicoSure product line for the treatment of tattoos, benign pigmented lesions, acne scars, fine lines, and wrinkles. The company also provides Icon aesthetic system for hair removal, wrinkle reduction, and scar and stretch mark treatment; Vectus diode laser for high volume hair removal; SculpSure hyperthermic laser treatment for LaserBodySculpting for non-invasive fat reduction; and MonaLisa Touch laser for gynecologic health. In addition, it markets radiofrequency energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry, and proctology. The company sells its products through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and South Korea, as well as through independent distributors in approximately 120 countries. Cynosure, Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.

People’s United Financial, Inc. (PBCT) traded within a range of $18.81 to $18.98 after opening the day at $18.85. The company has seen its stock decrease in value by -1.71% so far this year. The stock was up close to 0.64% on light volume in last trading session and closed at $18.86 per share. After the recent gain, the stock is currently holding -5.46% below its 52 week high of $20.13 and 43.45% above its 12-month low of $13.8. The shares are up by over 6.08% in the last three months, and the RSI indicator value of 49.64 is neither bullish nor bearish, tempting investors to stay on the sidelines.

People’s United Financial, Inc. operates as the bank holding company for People’s United Bank, National Association that provides commercial banking, retail banking, and wealth management services to individual, corporate, and municipal customers. The company operates in two segments, Commercial Banking and Retail Banking. The Commercial Banking segment offers commercial real estate lending, commercial and industrial lending, and commercial deposit gathering services. This segment also provides equipment financing; cash management, correspondent banking, and municipal banking services; and institutional trust, corporate trust, private banking, and insurance services. The Retail Banking segment offers consumer lending, including residential mortgage and home equity lending; and consumer deposit gathering services. This segment also provides brokerage, financial advisory, investment management, life insurance, and non-institutional trust services. In addition, the company offers online banking, investment trading, and telephone banking services. It operates through a network of 396 branches and 594 ATMs in Connecticut, southeastern New York, Massachusetts, Vermont, New Hampshire, and Maine. People’s United Financial, Inc. was founded in 1842 and is headquartered in Bridgeport, Connecticut.

 

Momentum Stocks in Focus: Sage Therapeutics, Inc. (SAGE) Threshold Pharmaceuticals Inc. (THLD) Discover Financial Services (DFS)

Sage Therapeutics, Inc. (SAGE) continued its downward trend with the stock declining -3.13% or $-1.26 to close the day at $39.01 on light trading volume of 3.25M shares, compared to its three month average trading volume of 928.67K. The  based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -30.71%, compared to the industry which has advanced 3.72% over the same period. With RSI of 49.94, the stock should still continue to rise and get closer to its one year target estimate of $71.38, making it a hold for now.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedation are desirable prior to the introduction of general anesthesia. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Threshold Pharmaceuticals Inc. (THLD) retreated with the stock falling -2.4% or $-0.03 to close at $1.22 on light trading volume of 3.25M compared its three months average trading volume of 3.33M. The South San Francisco California 94080 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -73.01% down for the period and up by 154.17% so far this year. With price target of $2 and a 480.95% rebound from 52-week low, Threshold Pharmaceuticals Inc. has plenty of upside potential, making it a hold with a view buy.

Threshold Pharmaceuticals, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Discover Financial Services (DFS) failed to extend gains with the stock declining -1.64% or $-0.98 to close the day at $58.74 on higher than average trading volume of 3.23M shares, compared to its three month average trading volume of 2.78M. The Riverwoods Illinois 60015 based company has been outperforming the credit services companies by 4.8652% for last three months and its recent gains have pushed the stock slightly up 11.36% YTD, versus the credit services industry which is up 2.17% for the same period. The RSI of 52.6 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Discover Financial Services operates as a direct banking and payment services company in the United States. It operates in two segments, Direct Banking and Payment Services. The Direct Banking segment offers Discover-branded credit cards to individuals; and other consumer products and services, including private student loans, personal loans, home equity loans, and other consumer lending, as well as deposit products, such as certificates of deposit, money market accounts, savings accounts, checking accounts, and individual retirement arrangement certificates of deposit. The Payment Services segment operates the Discover Network, which processes transactions for Discover-branded credit cards, and provides payment transaction processing and settlement services; and PULSE network, an electronic funds transfer network that provides financial institutions issuing debit cards on the PULSE network with access to automated teller machines and point-of-sale terminals. This segment also operates the Diners Club International, a payments network that issues Diners Club branded charge cards and provides card acceptance services. The company was incorporated in 1960 and is based in Riverwoods, Illinois.

 

Active Stocks in Review: American Capital Ltd. (NASDAQ:ACAS), TeamHealth Holdings Inc (NYSE:TMH), SAGE Therapeutics Inc (NASDAQ:SAGE)

American Capital Ltd. (NASDAQ:ACAS) fall -0.24% during last trading as the stock less -$0.04 to finish the day at $16.54 with about 914,011.00 shares changing hands, compared to its three month average trading volume of 933,315.00. The $3.55B market cap company, which fluctuated between $16.52 and $16.57 during the day, currently situated 38.76% above its 52 week low of $11.92 and -0.48% away from its one year high of $16.62. The RSI of 60.03 indicates the stock is overbought at the current levels, sell for now. American Capital, Ltd. (American Capital) is a global asset manager and private equity firm. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate, energy and structured products.

TeamHealth Holdings Inc (NYSE:TMH) fall -$0.07 to close the day at a new closing price of $34.74, a -0.07% decrease in value from its previous closing price that moved the stock 4.80% above its 52 week low of $33.15. A total of 913,556.00 shares exchanged hands during the day compared with its three month average trading volume of 559,688.00. The stock, which fluctuated between $34.13 and $35.09 during the day, currently situated -45.71% below its 52 week high. The stock is down by -19.08% in the past one month and down by -23.31% over the past three months. With a one year target estimate of $48.53 and RSI of 26.55, the stock still has upside potential, making it a hold for now. Team Health Holdings, Inc. (TeamHealth) is a provider of outsourced healthcare professional staffing and administrative services to hospitals and other healthcare providers. The Company operates through four segments: Hospital Based Services, IPC Healthcare, Specialty Services and Other Services.

SAGE Therapeutics Inc (NASDAQ:SAGE) had a light trading with around 910,709.00 shares changing hands compared to its three month average trading volume of 1.21M. The stock traded between $35.74 and $36.69 before closing at the price of $36.45 with 0.19% change on the day. The company is currently trading 38.70% above its 52 week low of $26.28 and -41.81% below its 52 week high of $62.64. Both the RSI indicator and target price of 42.98 and $77.00 respectively, lead us to believe that it could drop over the coming weeks. SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.